drugset / Trial / NCT03281187

Efficacy and Safety of Testosterone Nasal Gel for Treating Hypogonadism in Men.

NCT03281187

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a phase III study for evaluation of Nasotestt efficacy compared to Androgel in the treatment of male participants with hypogonadism condition (reduced levels of testosterone) that have clinical indication of hormonal replacement with testosterone.

Timeline

Start
2018-07-16
Primary completion
2018-11-12
Completion
2020-01-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Small molecule 5 mg Intranasal
Subject Testosterone Small molecule 50 mg Intranasal

Indications